Infection in the neutropenic and haematopoietic stem cell transplant recipient

被引:4
作者
Donnelly, JP [1 ]
机构
[1] Univ Nijmegen, Med Ctr, Dept Haematol, Nijmegen, Netherlands
关键词
D O I
10.1097/00001432-200008000-00002
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Patterns of bacterial infection have remained fairly static with Gram-positive bacteria predominating, although this varies between institutions and between patient populations, Similarly, antimicrobial resistance rates differ widely and reflect antibiotic use and exposure, Hence, each institution should devote microbiological resources to maintain surveillance and employ vigilance so that antimicrobial treatment protocols can be adapted to meet any new challenges, Most changes are being seen in the diagnosis of fungal infections, particularly aspergillosis, and the way in which it is being incorporated into treatment strategies, Curr Opin Infect Dis 13:337-342, (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:337 / 342
页数:6
相关论文
共 33 条
[21]  
Ramphal R, 1998, INT J HEMATOL, V68, pS21
[22]   Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation [J].
Ribaud, P ;
Chastang, C ;
Latgé, JP ;
Baffroy-Lafitte, L ;
Parquet, N ;
Devergie, A ;
Espérou, H ;
Sélimi, F ;
Rocha, V ;
Derouin, F ;
Socié, G ;
Gluckman, E .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (02) :322-330
[23]   Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy [J].
Rotstein, C ;
Bow, EJ ;
Laverdiere, M ;
Ioannou, S ;
Carr, D ;
Moghaddam, N .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (02) :331-340
[24]   Two strategies for managing invasive aspergillosis: A decision analysis [J].
Severens, JL ;
Donnelly, JP ;
Meis, JFGM ;
Robbe, PFD ;
DePauw, BE ;
Verweij, PE .
CLINICAL INFECTIOUS DISEASES, 1997, 25 (05) :1148-1154
[25]   Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward:: Clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes [J].
Siu, LK ;
Lu, PL ;
Hsueh, PR ;
Lin, FM ;
Chang, SC ;
Luh, KT ;
Ho, M ;
Lee, CY .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (12) :4020-4027
[26]   Specific detection of Aspergillus species in blood and bronchoalveolar lavage samples of immunocompromised patients by two-step PCR [J].
Skladny, H ;
Buchheidt, D ;
Baust, C ;
Krieg-Schneider, F ;
Seifarth, W ;
Leib-Mösch, C ;
Hehlmann, R .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (12) :3865-3871
[27]   Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity [J].
Sonis, ST .
ORAL ONCOLOGY, 1998, 34 (01) :39-43
[28]   Detection of antigen in sera of patients with invasive aspergillosis: Intra- and interlaboratory reproducibility [J].
Verweij, PE ;
Erjavec, Z ;
Sluiters, W ;
Goessens, W ;
Rozenberg-Arska, M ;
Debets-Ossenkopp, YJ ;
Guiot, HFL ;
Meis, JFGM .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (06) :1612-1616
[29]   Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC) [J].
Viscoli, C ;
Girmenia, C ;
Marinus, A ;
Collette, L ;
Martino, P ;
Vandercam, B ;
Doyen, C ;
Lebeau, B ;
Spence, D ;
Krcmery, V ;
De Pauw, B ;
Meunier, F .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) :1071-1079
[30]   A four-year review of fatal aspergillosis [J].
Vogeser, M ;
Wanders, A ;
Haas, A ;
Ruckdeschel, G .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1999, 18 (01) :42-45